BC
AKBA icon

Bartlett & Co’s Akebia Therapeutics AKBA Stock Holding History

Bartlett & Co’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$2K Buy
+500
New +$2.14K ﹤0.01% 816

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bartlett & Co's AKBA Position: Q3 2019 in Review

Bartlett & Co opened a new position in Akebia Therapeutics (AKBA) in Q3 2019: 500 shares worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #816 among its holdings.

150 funds tracked by Wall St. Rank hold AKBA as of Q3 2019.

  • Bartlett & Co held 500 shares of Akebia Therapeutics worth $2K as of Q3 2019.
  • Akebia Therapeutics was a new Bartlett & Co position in Q3 2019.
  • Akebia Therapeutics made up ﹤0.01% of Bartlett & Co's portfolio in Q3 2019, its #816 holding.
  • 150 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2019.

Based on Bartlett & Co's 13F filing for Q3 2019, filed 4 Nov 2019.